Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200301 (TNFR2 Agonist Antibody) as a Single Agent and in Combination With Tislelizumab (Anti-PD-1 Antibody) in Adult Patients With Advanced Solid Tumors

NCT05238883 is registered in ClinicalTrials.gov with HiFiBiO Therapeutics as lead sponsor.

NCT NCT05238883
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05238883 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200301 (TNFR2 Agonist Antibody) as a Single Agent and in Combination With Tislelizumab (Anti-PD-1 Antibody) in Adult Patients With Advanced Solid Tumors
Lead sponsor
HiFiBiO Therapeutics
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 10, 2022
Completion date
December 31, 2026
Enrollment
72 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, gastric cancer, head and neck squamous cell carcinoma, melanoma, mesothelioma, non small cell lung cancer, renal cell carcinoma, sarcoma, testicular germ cell tumor